OOIR: Observatory of International Research

Papers

(The TQCC of JAMA Neurology is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Facial Numbness, Dysarthria, Muscle Atrophy, and Weakness in a Young Patient	422
JAMA Neurology Peer Reviewers in 2020	364
Automated Imaging Differentiation for Parkinsonism	321
Error in Author Name	317
Adequate Initial Dosage and Tapering Methods of Steroids to Reduce the Total Corticosteroid Dose in Myasthenia Gravis	263
Optimizing the Time Course of Risks and Benefits of Acute Dual Antiplatelet Therapy for Stroke Prevention	257
Diplopia and Ptosis in an Older Woman	253
Origin of Transthyretin in Cerebral Amyloid Angiopathy	247
Early Access to First-Seizure Clinics, Subsequent Outcomes, and Factors Associated With Attendance	229
Association Between Increased Seizures During Rewarming After Hypothermia for Neonatal Hypoxic Ischemic Encephalopathy and Abnormal Neurodevelopmental Outcomes at 2-Year Follow-up	220
Early Posttraumatic Seizures—Putting Things in Perspective	204
Equipping AI for Unbiased and Inclusive Neurology	203
Itching Frequency and Neuroanatomic Correlates in Frontotemporal Lobar Degeneration	202
Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis	179
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation	176
Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study	176
A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials	173
Risk of Dementia in Individuals With Emergency Department Visits or Hospitalizations Due to Cannabis	170
Ghrelin for Neuroprotection in Post–Cardiac Arrest Coma	169
Association Between Treatment Progression, Disease Refractoriness, and Burden of Illness Among Hospitalized Patients With Status Epilepticus	164
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation	164
Substantia Nigra Pathology, Contact Sports Play, and Parkinsonism in Chronic Traumatic Encephalopathy	164
Alternate Hemibody Hyperkinetic and Hypokinetic Movement Disorders Due to Strategic Lesions in Cerebral Toxoplasmosis	161
JAMA Neurology	160
The Neurologist’s Imperative in Brain Death	159

Magnetic Resonance Imaging Features of Tropical Candidal Meningoencephalitis	154
Reinterpreting Clinical Trials in Children With Multiple Sclerosis Using a Bayesian Approach	153
Teleneurorehabilitation and Motor and Nonmotor Symptoms and Quality of Life in Parkinson Disease	150
Functional Outcomes in Conservatively vs Surgically Treated Cerebellar Infarcts	147
Time to Change the Current Clinical Classification of Multiple Sclerosis?	146
Healthy Life-Year Costs of Treatment Speed From Arrival to Endovascular Thrombectomy in Patients With Ischemic Stroke	143
Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers	143
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis	135
Time From Hospital Arrival Until Endovascular Thrombectomy and Patient-Reported Outcomes in Acute Ischemic Stroke	130
JAMA Neurology	126
Is It Really Itching?	125
Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome	124
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease	121
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation	117
Absent Blood Oxygen Level–Dependent Functional Magnetic Resonance Imaging Activation of the Orbitofrontal Cortex in a Patient With Persistent Cacosmia and Cacogeusia After COVID-19 Infection	115
Advanced Practice Clinicians—Neurology’s Underused Resource	114
Retinal Hemorrhage Associated with Human Granulocytic Anaplasmosis	113
Error in Abstract	113
Tackling the Unmet Therapeutic Needs in Nonsurgical Treatments for Epilepsy	112
Role of the X Chromosome in Alzheimer Disease Genetics	111
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias	109
Visual Neglect After an Isolated Lesion of the Superior Colliculus	108
N-Acetylcysteine for Hereditary Cystatin C Amyloid Angiopathy	107
Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology	102
Risk Factors Associated With Late-Onset Epilepsy in Dementia and Mild Cognitive Impairment	102
Endovascular Stroke Thrombectomy for Patients With Large Ischemic Core	100
Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease	98
Contribution of Somatic Ras/Raf/Mitogen-Activated Protein Kinase Variants in the Hippocampus in Drug-Resistant Mesial Temporal Lobe Epilepsy	97
Error in Figure	96
Disentangling Workflow Paradigms and Treatment Decision-making in Acute Ischemic Stroke	94
Error in Figure	93
Errors in Figure 2	92
Histologic Anatomy of Neurocysticercosis	91
Error in Additional Contributions	89
Association of Cardiovascular Events With Spouse’s Subsequent Dementia	88
Spontaneous AICA Dissection Presenting With Isolated Audiovestibular Loss	86
Sleep Recording for the Diagnosis and Treatment of Paraplegia	83
Is It Really Itching?—Reply	82
β-Amyloid Positron Emission Tomography Use Across Medicare Administrative Contractor Regions	81
JAMA Neurology	81
Spinal Cerebrospinal Fluid Leak Mimicking a Cerebellopontine Angle Tumor	81
Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke	80
Functional Seizures—A Critical Comorbidity Overlooked in Epilepsy Research—Reply	79
Do Neurologists Need a Goldwater Rule?	78
Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures	78
Methylphenidate for Apathy in Alzheimer Disease—Why Should We Care?	77
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum	75
Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion	75
Acute Myelopathy in a Man With Cutaneous Papules	74
Visualization of Parkinsonian Tongue Tremor on Ultrasonography	74

JAMA Neurology	74
JAMA Neurology	73
Error in Text	72
Magnetic Resonance Imaging Features of GABA-A Receptor Antibody-Mediated Encephalitis	72
Perceived CTE and Suicidality—Is Perception Reality?	70
Error in Figures	70
Error in Key for Figure 3	69
The Trade-off Between the Bony Carotid Canal and Internal Carotid Artery	69
Administering Thrombolysis for Acute Ischemic Stroke in Patients Taking Direct Oral Anticoagulants	68
Peripheral-Type Facial Paralysis and Unilateral Hemisphere Hemorrhage	66
AI Devices in Neurology—Moving From Diagnosis to Prognosis	65
The Impact of Stuttering—Hiding in Plain Sight	65
Bibrachial Amyotrophy Due to Spontaneous Spinal Cerebrospinal Fluid Leak	65
Expanding Clinical Spectrum of Anti-GQ1b Antibody Syndrome	64
Functional Impairment in Individuals With Prodromal or Unrecognized Parkinson Disease	64
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis	63
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease	63
A Rare Neurological Presentation of Kikuchi-Fujimoto Disease	63
The New Era of Automated Electroencephalogram Interpretation	63
Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke	62
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers	62
Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	62
The Semont-Plus Maneuver or the Epley Maneuver in Posterior Canal Benign Paroxysmal Positional Vertigo	61
Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura	59
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis	58
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients	58
Repairing Our View of Dementia	58
Association of NO₂ and Other Air Pollution Exposures With the Risk of Parkinson Disease	58
Comparison of Perinatal Outcomes for Women With and Without Epilepsy	58
Choosing the Best Antiseizure Medication—Can Artificial Intelligence Help?	57
Concerns Remain Regarding Ambient NO₂ Exposure and the Risk of Parkinson Disease—Reply	57
The Choreoathetotic Movement of Paroxysmal Nonkinesigenic Dyskinesia	57
Error in Text	57
Livedo Reticularis—A Presenting Sign of Neuromyelitis Optica Spectrum Disorder	56
Error in Title	56
Primary Central Nervous System Lymphoma With Symmetrical Pyramidal Tract Hyperintensity	56
JAMA Neurology Peer Reviewers in 2021	56
JAMA Neurology	56
Addition of Video Titles	56
Benefits and Risks of Periconceptional Folic Acid Supplementation	55
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography	54
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis	54
Benefits and Risks of Periconceptional Folic Acid Supplementation—Reply	54
Novel Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies	53
IWG and AA Criteria—Where the Differences Matter—Reply	53
Expanding the Prion Paradigm to Include Alzheimer and Parkinson Diseases	53
Cerebral Amyloid Angiopathy—How to Translate Updated Diagnostic Criteria for This Multifaceted Disorder to Clinical Practice?	53
Coma Prognostication After Acute Brain Injury	53
Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest	53
Adverse Childhood Experiences, Toxic Stress, and Trauma-Informed Neurology	52
SARS-CoV-2 Vaccination and Neuroimmunological Disease	52
Possible Explanations for Hearing Loss in Parkinson Disease	52
Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow	51
Association Between Acute Myocardial Infarction and Cognition	51
Monogenic Stroke—Can We Overcome Nature With Nurture?	51
Cognitive Behavioral Therapy for Veterans With Comorbid Posttraumatic Headache and Posttraumatic Stress Disorder Symptoms	51
JAMA Neurology	50
Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis—Variations in Real-World Experience—Reply	50
Error in Author Name	50
How Is the X Chromosome Involved in Alzheimer Disease?	49
Addition of Nonauthor Collaborators and a Supplement	49
A Woman With Eosinophilic Brainstem Meningoencephalitis	49
The Perils and Pitfalls of Global Engagement	49
Traumatic Brain Injury Recovery Trajectories in Patients With Disorders of Consciousness	49
SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort	48
Transcarotid Artery Revascularization for Stroke Prevention—Multiple Elephants in the Room	48
Views From Both Sides of the White Coat	47
Statewide Emergency Medical Services Protocols for Suspected Stroke and Large Vessel Occlusion	47
Errors in Figure 2 and the Short Title	46
Discerning the Role of Autoimmunity and Autoantibodies in Epilepsy	45
Gantenerumab in Dominantly Inherited Alzheimer Disease—Reply	45
The End Justifies the Means—A Call for Nuance in the Increasing Nationwide Adoption of Stereoelectroencephalography Over Subdural Electrode Monitoring in the Surgical Evaluation of Intractable Epileps	45
Citius, Fortius, Altius—Understanding Which Components Drive Exercise Benefits in Parkinson Disease	45
Error in Author Affiliation	44
Medical Forecasting—A Skill Set Worthy of Attention	44
Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis	44
Association of Aortic Stiffness and Pressure Pulsatility With Global Amyloid-β and Regional Tau Burden Among Framingham Heart Study Participants Without Dementia	43
Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors	43
Association Between Antiseizure Drug Monotherapy and Mortality for Patients With Poststroke Epilepsy	42
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis	42

Exome Sequencing and the Identification of New Genes and Shared Mechanisms in Polymicrogyria	42
TDP-43 Accumulation Within Intramuscular Nerve Bundles of Patients With Amyotrophic Lateral Sclerosis	41
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants	41
Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios	41
Structural Inequities for Historically Underserved Communities in the Adoption of Stroke Certification in the United States	41
One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China	41
Visual Impairment as a Modifiable Risk Factor in Dementia Prevention and Management	41
Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died	40
Modern Neurology Training Is Failing Outpatients	40
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease	40
Error in Title	39
Venture Capital Investment in Neurology Companies	39
Error in Open Access Status	39
Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing	39
Bilateral Complete Ophthalmoplegia in a 50-Year-Old Man	39
Flapping Scalp Sign as a Rare and Interesting Presentation in Delayed Postoperative Tension Pneumocephalus	38
JAMA Neurology	38
Batoclimab vs Placebo for Generalized Myasthenia Gravis	37
Error in Figures 2 and 3	37
CC-BY Open Access Added	37
A 51-Year-Old Woman With Abnormal Corpus Callosum Signal	37
JAMA Neurology	36
Acute Ischemic Stroke Care Quality Improvement	36
Risks of Expanded Medicare Coverage of Carotid Artery Stenting	36
Discussion on the Application of Rapid Immunoblot Assay for AQP4-IgG Detection	36
Multimodal Neuroimaging of Intimal Flap in a Basilar Artery Dissection	35
Recurrent Ischemic Stroke in Patients With Atrial Fibrillation While Receiving Oral Anticoagulants	35
Genome Sequencing After Exome Sequencing in Pediatric Epilepsy	34
Physical Frailty, Genetic Predisposition, and Incident Parkinson Disease	34
Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?	33
Neurologic Complications of Smallpox and Monkeypox	33
An Acetylcholine M₁ Receptor–Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment	32
Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients With Large Ischemic Strokes	32
Risk of Stroke, Death, and Myocardial Infarction Following Transcarotid Artery Revascularization vs Carotid Endarterectomy in Patients With Standard Surgical Risk	32
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine	32
Immediate- or Delayed-Intensive Statin in Acute Cerebral Ischemia	32
Multisite Skin Biopsies vs Cerebrospinal Fluid for Prion Seeding Activity in the Diagnosis of Prion Diseases	32
Targeting Sleep and Circadian Function in the Prevention of Alzheimer Disease	31
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease	31
White Matter Tract Density Index Prediction Model of Overall Survival in Glioblastoma	31
Directly Isolated Allogeneic Virus–Specific T Cells in Progressive Multifocal Leukoencephalopathy	31
Reperfusion Treatment and Stroke Outcomes in Hospitals With Telestroke Capacity	31
Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia	31
Risk Factors for Young-Onset Dementia in the UK Biobank	31
Development and Validation of a Deep Learning Model for Predicting Treatment Response in Patients With Newly Diagnosed Epilepsy	30
Transient Focal Neurological Events in Cerebral Amyloid Angiopathy and the Long-term Risk of Intracerebral Hemorrhage and Death	30
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels	29
Neuro-Advocacy—Professionalism in Action	29
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease	29
Error in Methods	29
Error in Figure 2	29
Quality Improvement Intervention for Reducing Acute Treatment Times in Ischemic Stroke	28
Inducers and Cardiovascular Risk—Potential Role for Lowered Drug Exposure	28
Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers	28
Light Reading—The Gravity of Postoperative Care	28
A Funeral for a Neurologist	28
E-Cigarettes and Stroke Risk—Present Uncertainties and Future Directions	28
APOE ε4 Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome—Implications for Clinical Trials and Treatments for All	27
Remembering the Physician’s Humanity—Physicians Are Humans Too	27
Paused—A Residency Interrupted	27
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms	27
Entering Medicine as a Physician and a Patient	27
Association Between Use of Angiotensin Receptor Blockers and Incidence of Epilepsy in Patients With Hypertension—Reply	27
Local Cerebral Recombinant Tissue Plasminogen Activator Concentrations During Acute Stroke	27
Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19	26
Association of Tourette Syndrome and Chronic Tic Disorder With Violent Assault and Criminal Convictions	26
Effect of Irrigation Fluid Temperature on Recurrence in the Evacuation of Chronic Subdural Hematoma	26
Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor	26
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity	26
Embedded Human Closed-Loop Deep Brain Stimulation for Tourette Syndrome	26
What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?	26
Multiple Facial Ulcers Following a Stroke	26
Error in Figure 2B	25
Error in Figure 1	25
JAMA Neurology	25
Trends in AVM-Associated Intracranial Hemorrhage in the United States, 2000-2019	25
A Decision With Love	24
Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database	24
Bilateral Calcification of the Meckel Cave Causing Hemicrania Continua	24
Error in Title	24
How SAFE Is Real-world Use of Spinal Cord Stimulation Therapy for Chronic Pain?	24
Central Retinal Artery Occlusion With Cilioretinal Artery Sparing After Semaglutide Injection	24
Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease—Reply	24
Abnormal Movements in Bickerstaff Brainstem Encephalitis Mimicking Anti–N-Methyl-d-Aspartate Receptor Encephalitis	24
Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease	24
Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events	23
Anticoagulation in ESUS—Back From the Dead?	23
Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage	23
Research Criteria for the Behavioral Variant of Alzheimer Disease	23
Risk of Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor–Inhibitor Treatment for Autoimmune Diseases	23
Oncogenic Pathways Provide Clue to the Etiology of Human Mesial Temporal Lobe Epilepsy	22
Errors in Results in Abstract and Text and in Table 1	22
Sex Differences in Case-Fatality Rates of Stroke—Reply	22
JAMA Neurology—The Year in Review, 2023	22
Immortal Time Bias and Nonlinear Stroke Recurrence Risk—Reply	22